Design and Characterization of a Dual-Protein Strategy for an Early-Stage Assay of Ovarian Cancer Biomarker Lysophosphatidic Acid
Biosensors · 2024
DOI: 10.3390/bios14060287 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biosensors, 2024. Verfasst von Katharina Davoudian und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, University of Toronto, 80 St. George Street, Toronto, ON M5S 3H6, Canada. Hauptthemen laut MEDLINE: Lysophospholipids, Ovarian Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science Agency VEGA, European Union’s Horizon 2020 research and innovation program, Canadian Institutes of Health Research.
Abstract (Originalsprache)
The overall 5-year survival rate of ovarian cancer (OC) is generally low as the disease is often diagnosed at an advanced stage of progression. To save lives, OC must be identified in its early stages when treatment is most effective. Early-stage OC causes the upregulation of lysophosphatidic acid (LPA), making the molecule a promising biomarker for early-stage detection. An LPA assay can additionally stage the disease since LPA levels increase with OC progression. This work presents two methods that demonstrate the prospective application for detecting LPA: the electromagnetic piezoelectric acoustic sensor (EMPAS) and a chemiluminescence-based iron oxide nanoparticle (IONP) approach. Both methods incorporate the protein complex gelsolin–actin, which enables testing for detection of the biomarker as the binding of LPA to the complex results in the separation of gelsolin from actin. The EMPAS was characterized with contact angle goniometry and atomic force microscopy, while gelsolin–actin-functionalized IONPs were characterized with transmission electron microscopy and Fourier transform infrared spectroscopy. In addition to characterization, LPA detection was demonstrated as a proof-of-concept in Milli-Q water, buffer, or human serum, highlighting various LPA assays that can be developed for the early-stage detection of OC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, University of Toronto, 80 St. George Street, Toronto, ON M5S 3H6, Canada.
- Faculty of Mathematics, Physics and Informatics, Comenius University, Mlynská dolina F1, 842 48 Bratislava, Slovakia.
- Functional Interfaces Research Group, Institute of Materials and Environmental Chemistry, HUN-REN Research Centre for Natural Sciences, Magyar tudósok krt. 2., H-1117 Budapest, Hungary.
ORCID-Profile: Katharina Davoudian, Sandro Spagnolo, Navina Lotay, Monika Satkauskas, Gábor Mészáros, Tibor Hianik, Zsófia Keresztes, Michael Thompson
Förderung
- Science Agency VEGA
- European Union’s Horizon 2020 research and innovation program
- Canadian Institutes of Health Research
Zitieren
APA
Davoudian, K., Spagnolo, S., Lotay, N., Satkauskas, M., Mészáros, G., Hianik, T., Keresztes, Z., Walker, G., & Thompson, M. (2024). Design and Characterization of a Dual-Protein Strategy for an Early-Stage Assay of Ovarian Cancer Biomarker Lysophosphatidic Acid. Biosensors. https://doi.org/10.3390/bios14060287
Vancouver
Davoudian K, Spagnolo S, Lotay N, Satkauskas M, Mészáros G, Hianik T, et al. Design and Characterization of a Dual-Protein Strategy for an Early-Stage Assay of Ovarian Cancer Biomarker Lysophosphatidic Acid. Biosensors. 2024. doi:10.3390/bios14060287
BibTeX
@article{Davoudian2024,
author = {Davoudian, Katharina and Spagnolo, Sandro and Lotay, Navina and Satkauskas, Monika and Mészáros, Gábor and Hianik, Tibor and Keresztes, Zsófia and Walker, Gilbert and Thompson, Michael},
title = {Design and Characterization of a Dual-Protein Strategy for an Early-Stage Assay of Ovarian Cancer Biomarker Lysophosphatidic Acid},
journal = {Biosensors},
year = {2024},
doi = {10.3390/bios14060287}
}
EUVIMED